leadf
logo-loader
viewCytoDyn Inc.

CytoDyn to meet with FDA to discuss prostate cancer-detection test

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan revealed Monday that the FDA has granted company executives a meeting in August this year to discuss the company’s 510(k) application for clearance of its ProstaGene Prognostic Test.

What's more, Dr Pourhassan talked about a second tender offer filed Monday that will bring in nearly $18 million in funds.

Quick facts: CytoDyn Inc.

Price: 3.37 USD

OTCQB:CYDY
Market: OTCQB
Market Cap: $1.92 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

CytoDyn addresses WSJ & SeekingAlpha articles, calls on investors to pay...

CytoDyn Inc. (OTCQB:CYDY) CEO Nader Pourhassan addresses the recent articles published by the Wall Street Journal and SeekingAlpha, in regards to its participation in Operation Warp Speed. Pourhassan says shareholders should pay attention to the group's fundamentals, adding to 'only buy the...

on 08/26/2020

2 min read